Interview with Amalia Sapag, PhD
Science: Q: Paul Zamecnik and Mary Stephenson in 1978 reported the very first studies on antisense mechanisms of gene silencing. Since the inception of this field – how far have we come – both in basic and therapeutic research & development? A: The original antisense mechanism has been joined
Interview with Mirjana Kujacic, PhD
Science: Q: Paul Zamecnik and Mary Stephenson in 1978 reported the very first studies on antisense mechanisms of gene silencing. Since the inception of this field – how far have we come – both in basic and therapeutic research & development? A: The original antisense mechanism has been joined
Interview with Marcin Kortylewski, PhD
Marcin Kortylewski, Ph.D. Associate Professor Department of Immuno-Oncology Beckman Research Institute City of Hope National Medical Center How did you become interested in the field of oligonucleotides? Rather late, after about ten years of graduate and postdoctoral research on signal transduction and tumor immunology ...
Interview with Peter A. Beal, PhD
Peter A. Beal, Ph.D., Professor Department of Chemistry University of California, Davis How did you become interested in the field of oligonucleotides? My interests in therapeutic oligonucleotides can be traced back to my time as an undergraduate student at the University of North Dakota. ...
Interview with Jessica Rouge, PhD
Jessica Rouge, Ph.D., Assistant Professor Chemistry Department University of Connecticut How did you become interested in the field of oligonucleotides? One day I participated in a weekend biotechnology class at a community college that was designed for high school students where I ran a ...
Interview with Michael P. Gantier, PhD
Michael P. Gantier, Ph.D. Group leader, Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Monash University, Melbourne Australia How did you become interested in the field of oligonucleotides? I started my Ph.D. mid 2002 at University College Dublin (UCD), ...
Interview with Kalyan Dulla, PhD, MBA
Kalyan Dulla, PhD, MBA Director Non-Clinical Research ProQR Therapeutics How did you become interested in the field of oligonucleotides? Although I had been aware of the use of antisense oligonucleotides for (m)RNA knockdown or as aptamers since my university days I was not ...
Interview with Daniel O’Reilly, PhD Candidate
Daniel O’Reilly MChem, PhD Candidate McGill University How did you become interested in the field of oligonucleotides? My introduction to the world of genetic disease and oligonucleotides came at an early age when my mum was diagnosed with Huntington’s Disease (HD). Witnessing the ...
Interview with Nagy Habib, ChM, FRCS
Professor Henri Bismuth, pioneer and renowned international expert in the field of hepatobiliary disease who set up the first liver transplant Centre in France.
Interview with Pad Chivukula, PhD
My mentor helped me to see the potential of pharmaceutical research on our society.
